Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mytrex Health TechnologiesROCO:4431 +1.45%64 PS Ratio is 0.33 as of Jul. 27, 2026, which is 65% below its 10-year median of 0.95. GuruFocus rates ROCO:4431 with a GF Score™ of 64/100 and a GF Value™ of NT$37.25 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 3,026 Industrial Products companies, Mytrex Health Technologies ranks better than 92.7% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Mytrex Health Technologies's share price is NT$17.50.
Mytrex Health Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$53.23. Hence, Mytrex Health Technologies's PS Ratio for today is 0.33.
Good Sign:
Mytrex Health Technologies Inc stock PS Ratio (=0.32) is close to 10-year low of 0.31.
The historical rank and industry rank for Mytrex Health Technologies's PS Ratio or its related term are showing as below:
ROCO:4431'
s PS Ratio Range Over the Past 10 Years
Min: 0.31 Med: 0.95 Max: 9.83
Current: 0.32
During the past 13 years, Mytrex Health Technologies's highest PS Ratio was 9.83. The lowest was 0.31. And the median was 0.95.
ROCO:4431's PS Ratio is ranked better than 92.7% of 3026
companies
in the Industrial Products industry
Industry Median: 1.93
vs ROCO:4431: 0.32
Mytrex Health Technologies Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Mytrex Health Technologies was 10.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 9.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 25.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 16.60% per year.
During the past 13 years, Mytrex Health Technologies's highest 3-Year average Revenue per Share Growth Rate was 82.00% per year. The lowest was -18.10% per year. And the median was 5.05% per year.
Back to Basics: PS Ratio
Mytrex Health Technologies (ROCO:4431) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Mytrex Health Technologies PS Ratio Related Terms
Mytrex Health Technologies PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Industrial Machinery subindustry, Mytrex Health Technologies's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mytrex Health Technologies PS Ratio vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Mytrex Health Technologies's PS Ratio distribution charts can be found below:
* The bar in red indicates where Mytrex Health Technologies's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Mytrex Health Technologies's Share Price of today is NT$17.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mytrex Health Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$53.23.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Mytrex Health Technologies (ROCO:4431) has a PS Ratio of 0.33 as of Jul. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Mytrex Health Technologies and its competitors. This is 65% below median its historical median of 0.95. Over the past decade, Mytrex Health Technologies' PS Ratio has ranged from 0.31 to 9.83. According to the industry distribution chart, Mytrex Health Technologies ranks #221 out of 3026 companies in the Industrial Products industry, placing it in the top 7.3%.
Is Mytrex Health Technologies' PS Ratio too high?
Mytrex Health Technologies' current PS Ratio of 0.33 is 65% below median its 10-year median of 0.95. Over the past 10 years, this metric has ranged from a low of 0.31 to a high of 9.83. The Industrial Products industry median PS Ratio is 1.93. Mytrex Health Technologies' value of 0.33 is 82.9% below this industry median. Based on the distribution chart, Mytrex Health Technologies ranks #221 out of 3026 companies in the Industrial Products industry, which is in the top quartile — a strong position relative to peers. Overall, Mytrex Health Technologies has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mytrex Health Technologies' PS Ratio compare to GEV and ETN?
According to the Industrial Products industry distribution chart, Mytrex Health Technologies ranks #221 out of 3026 companies for PS Ratio. This places Mytrex Health Technologies in the top 7% of its industry — outperforming the majority of peers. The industry median PS Ratio is 1.93. Mytrex Health Technologies' value of 0.33 is 82.9% below this benchmark. Historically, Mytrex Health Technologies' own PS Ratio has ranged from 0.31 to 9.83 over the past decade. While the company's 10-year median is 0.95 vs. the industry median of 1.93, Mytrex Health Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for an Industrial Products company?
The median PS Ratio among Industrial Products companies is 1.93, based on 3,026 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mytrex Health Technologies's current PS Ratio of 0.33 is 82.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Mytrex Health Technologies and its competitors. For the Industrial Products industry, the median PS Ratio is 1.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mytrex Health Technologies's current PS Ratio is 0.33, which is 65% below median its own 10-year median of 0.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mytrex Health Technologies stock overvalued right now?
Based on GuruFocus' analysis, Mytrex Health Technologies (ROCO:4431) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$37.25, compared to a current price of NT$17.50 — trading 53% below its estimated fair value. The current PS Ratio is 0.33, which is 65% below median its 10-year median of 0.95 and 82.9% below the Industrial Products industry median of 1.93. Mytrex Health Technologies' overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Mytrex Health Technologies (ROCO:4431), the current PS Ratio is 0.33 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mytrex Health Technologies (ROCO:4431) Overvalued in 2026?
Based on GuruFocus' analysis, Mytrex Health Technologies stock appears to be undervalued.
The current stock price of NT$17.50 is trading 53% below its estimated GF Value™ of NT$37.25.
GuruFocus considers Mytrex Health Technologies to be Significantly Undervalued.
Key valuation signals for ROCO:4431:
PS Ratio: 0.33 (65% below median its 10-year median of 0.95)
GF Value™: NT$37.25 vs. price of NT$17.50 (53% below fair value)
Industry Position: 82.9% below the Industrial Products median (#221 of 3026)
No single metric tells the full story. See the ROCO:4431 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mytrex Health Technologies Inc is a Taiwan-based company engaged in the manufacturing of non-woven materials and special medical supplies. It is engaged in the development and production of melt-blown products for the protection of the environment and human health. The company offers products ranging from medical to industrial filtration materials such as various types of filtration media, lab coats or outfits, cabin filtration, vacuum cleaner filter bags, and special medical supplies. Its product categories include meltdown, mammoth bedding, and specialized medical supplies like balloon catheters and coronary stents.
64GF Score
Get the complete analysis for ROCO:4431
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4431 has been successfully added to your 
